Half Year 2026 Fagron NV Earnings Call Transcript
Key Points
- Fagron SA (ARSUF) reported strong H1 2026 results with revenues reaching EUR552 million, reflecting 3.1% organic growth at CER, and adjusted EBITDA growing 12.7% to EUR107 million.
- The company completed five acquisitions in 2026, including Amber in Asia and Purifarma and Vepakum in Latin America, with all acquisitions performing as expected or better and contributing EUR69 million to revenues.
- EMEA and Latin America delivered solid organic growth of 4.1% and 8% at CER, respectively, with margin expansion of 30 and 120 basis points, driven by operational excellence and integration synergies.
- The company is well-positioned for future growth with capacity expansion projects on track, including a new 503A facility in Tampa with $100 million revenue potential and 503B facilities in Wichita and Las Vegas with combined $315 million revenue potential.
- The PCAC recommendation to include six peptides in the 503A Bulks list is seen as a tailwind, and Fagron's existing infrastructure and track record position it to capture this opportunity.
- Operating cash flow improved by 10.8% year-on-year to EUR58.1 million, demonstrating strong cash generation capabilities.
- The company reiterated its full-year guidance of mid- to high-single-digit organic growth and an adjusted EBITDA margin of around 20%, with confidence in a stronger second half.
- New leadership appointments, including Amy Jones for North America Pacific and Kenneth Bonnell as Global Head of Quality, bring extensive experience to support growth and quality initiatives.
- North America Pacific revenue was largely flat with 0.2% organic growth at CER, impacted by the normalization of GLP-1-related revenues and an industry-wide IV bag recall, leading to a temporary margin decline.
- Gross margin decreased by 218 basis points year-on-year, driven by acquisitions and a change in product mix in North America Pacific.
- Net debt increased significantly to EUR505.4 million, with net debt to EBITDA rising to 2.1 times, largely due to acquisition payments, though still below the internal threshold of 2.8 times.
- The IV bag availability issue is expected to persist into Q3, with a gradual recovery in compounding services activity only expected to accelerate in Q4, impacting near-term growth.
- Free cash flow conversion was below guidance at 40.9% when adjusting for one-off CapEx, due to higher working capital from acquisitions and inventory buildup.
- The company faces potential headwinds from raw material price increases, particularly oil-derived items, and geopolitical turmoil in the Middle East, though it has the ability to pass on price increases.
- The integration of acquisitions, such as Pharmavit, is dilutive to margins in the short term, with synergies expected to materialize over an 18-24 month period.
- The timing of peptide market opportunities is uncertain, with revenue potential only expected 6-18 months after FDA inclusion, which is not guaranteed.
Hello and good morning, everyone. Welcome to Fagron's H1 2026 results webcast.
I'm joined today by our CEO, Rafael Padilla, and our CFO, Karin de Jong. Rafael will start by discussing the company's performance and a closer look at regional developments. Karin will then walk you through the financial results. We will open the floor for questions at the end of the session.
With that. I will hand over to Rafael.
Thanks, Ignacio, and good morning, all. We're pleased to report a strong performance with revenues reaching EUR552 million. This reflects 3.1% organic growth at CER, 7% were normalizing the GLP-1 effect. Growth was driven by brands, Latin America, B&E North America and EMEA.
Profitability grew by 12.7% to EUR107 million. The margin of 19.4% reflects an improvement in both EMEA and Latin America and temporary effects in North America Pacific compounding services. On M&A, we closed the
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
